Abata Therapeutics is expected to launch a Phase 1 clinical trial by the end of the year to test ABA-101, its experimental therapy for progressive multiple sclerosis (MS), after getting a green light from the U.S. Food and Drug Administration (FDA).
The FDA approved Abata’s investigational new drug (IND) application for ABA-101 in progressive MS, a patient population with few therapeutic options. ABA-101 works by modifying a type of immune cell known as regulatory T-cells, or Tregs.
That decision cleared the way for this first-in-human trial, which will test the treatment candidate in patients with progressive MS.
Read full story HERE…